https://www.businesswire.com/news/home/20250513753037/en/Verastem-Oncology-Reports-First-Quarter-2025-Financial-Results-and-Highlights-Recent-Business-Updates?feedref=Zd8jjkgYuzBwDixoAdXmJgT1albrG1Eq4mAeVP39211KIY8dqRJOTu36zg5ojSWrevRMp3sIgu8q3wq1OF24lT93qbEzrwa15HGbLqMObxYjwPpKemorG67JEVtPrh6fM-qD99V7nLhHRG_XnYInrw%3D%3D
Verastem Oncology Reports First Quarter 2025 Financial Results and Highlights Recent Business...
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today a...
oncology reportsfirst quarter
https://www.businesswire.com/news/home/20260402851535/en/Verastem-Oncology-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635c4
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today a...
https://www.southampton.ac.uk/research/projects/a-al-shamkhani-verastem-inc-combinations-of-immunostimulatory-antibodies-a-fak
A Al-Shamkhani - Verastem Inc - Combinations of immunostimulatory antibodies and a FAK inhibitor...
A Al-Shamkhani - Verastem Inc - Combinations of immunostimulatory antibodies and a FAK inhibitor for the treatment of cancer.
https://www.fool.com/investing/2018/05/16/why-verastem-stock-is-plunging-today.aspx
Why Verastem Stock Is Plunging Today | The Motley Fool
May 16, 2018 - The biotech is raising cash ahead of a potential launch of its first drug.
the motleyverastemstockplungingtoday